Latest Articles
- Common infectious complications of liver transplant
The risk and the likely organisms vary with the patient’s state of immunosuppression and the time after transplant.
- Recreational cannabis use: Pleasures and pitfalls
The legalization of cannabis and its increased potency today are leading to complications hitherto unseen.
- Stellate ulceration in a nonuremic patient
Calciphylaxis is a poorly understood small-vessel vasculopathy most often associated with end-stage renal disease.
- Noncosmetic uses of botulinum toxin in otolaryngology
It is used for spasmodic dysphonia, essential tremor of the voice, and dysphagia due to cricopharyngeal dysfunction.
- Should all patients with significant proteinuria take a renin-angiotensin inhibitor?
Most of them should, with exceptions due to adverse effects such as angioedema, cough, and hyperkalemia.
- Sacubitril-valsartan and the evolution of heart failure care
It was hard to believe that any new additional therapy would make a significant difference.
- Resuming anticoagulation after hemorrhage (April 2015)
Readers comment on resuming anticoagulation after hemorrhage (April 2015) and on starting insulin therapy in patients with type 2 diabetes (August 2015).
- Genitourinary manifestations of sickle cell disease
Sickling can lead to nephropathy, priapism, papillary necrosis, and renal medullary carcinoma.
- Do healthy patients need routine laboratory testing before elective noncardiac surgery?
Testing often increases costs and anxiety, with little benefit.
A new class of drugs for systolic heart failure: The PARADIGM-HF studyValsartan-sacubitril is the first new drug in over a decade to decrease death rates in patients with systolic heart failure.
